Phosphonate linkers and their use to facilitate cellular retention of compounds

1. A method for treating a disease or disorder by providing to a subject having the disease or disorder a composition comprising a compound having formula (III)

wherein V is selected from O and S; W is selected from a bivalent, straight or branched, saturated or unsaturated, optionally substituted C 1-30 hydrocarbon chain wherein one or more methylene units are optionally and independently replaced by —O—, —S—, —N(R)—, —C(O)—, C(O)O—, OC(O)—, —N(R)C(O)—, —C(O)N(R)—, —S(O)—, —S(O)2-, —N(R)SO2-, SO2N(R)—, a heterocyclic group, an aryl group, or a heteroaryl group;

X is a tuning element selected from a covalent bond; a carbon atom; a heteroatom; an optionally substituted group selected from the group consisting of acyl, aliphatic, heteroaliphatic, aryl, heteroaryl, and heterocyclic; nucleoside, protease sensitive group, cathepsin B sensitive group, or glycosidase sensitive group;

Y is selected from a covalent bond or a bivalent, straight or branched, saturated or unsaturated, optionally substituted C 1-30 hydrocarbon chain wherein one or more methylene units are optionally and independently replaced by —O—, —S—, —N(R)—, —C(O)—, C(O)O—, OC(O)—, —N(R)C(O)—, —C(O)N(R)—, —S(O)—, —S(O)2-, —N(R)SO2-, SO2N(R)—, a heterocyclic group, an aryl group, or a heteroaryl group;

D is a payload;

Z is a linkage formed between (i) a reactive functional group selected from the group consisting of N-hydroxysuccinimide, para-nitrophenyl carbonate, para-nitrophenyl carbamate, pentafluorophenyl, haloacetamide, maleimide, hydroxylamine, strained cycloalkyne, heterocycloalkyne, alkyne, diene, azadiene, and heterocyclic azadience, wherein halo is iodine (I), bromine (Br), fluorine (F), or chlorine (Cl) and hetero is N, O, or S, and (ii) an S, NR, or 0 group on L;

each occurrence of R is independently hydrogen, a suitable protecting group, an acyl moiety, arylalkyl moiety, aliphatic moiety, aryl moiety, heteroaryl moiety, or heteroaliphatic moiety;

L is a cell-specific targeting ligand; and n is 1, 2, 3, or 4; and

a pharmaceutically acceptable salt or carrier.

2. The method of claim 1 , wherein the payload is a therapeutic agent.

3. The method of claim 2 , wherein the therapeutic agent is a cytotoxic agent, anti-inflammatory agent, peptide, nucleic acid, or nucleic acid analog.

4. The method of claim 3 , wherein the anti-inflammatory agent is a glucocorticoid receptor agonist.

5. The method of claim 3 , wherein the anti-inflammatory agent is cortisol, cortisone acetate, beclometasone, prednisone, prednisolone, methylprednisolone, betamethasone, trimcinolone, budesonide, dexamethasone, fluticasone, or mometasone.

6. The method of claim 1 , wherein the targeting ligand is a chimeric antibody, humanized antibody, human antibody, ligand for a receptor, lectin, saccharide, poly(ethylene glycol), polysaccharide, or polyamino acid.

7. The method of claim 1 , wherein the targeting ligand is a chimeric, humanized, or human anti-Her2 antibody, anti-CD4 antibody, anti-CD20 antibody, anti-EGFR antibody, anti-CD22 antibody, anti-CD23 antibody, anti-CD25 antibody, anti-CD52 antibody, anti-CD30 antibody, anti-CD33 antibody, anti-CD40L antibody, anti-CD70 antibody, anti-CD74 antibody, anti-CD80 antibody, anti-CD163 antibody, anti-Mud8 antibody, anti-integrin antibody, anti-PSMA antibody, anti-CEA antibody, anti-CD1 Ia antibody, anti-CTLA4 antibody, or anti-BLys antibody.

8. The method of claim 3 , wherein the cytotoxic agent is selected from duocarmycins and CC-1065.

9. The method of claim 3 , wherein the cytotoxic agent is selected from CBI (1,2,9,9a- tetrahydrocyclopropa[c]benz[e]indol-4-one)-based analogues, MCBI (7-methoxy- 1,2,9,9a- tetra-hydrocyclopropa[c]benz[e]indol-4-one)-based analogues and CCBI (7-cyano- 1,2,9,9a- tetra-hydrocyclo-propa[c]benz[e]-indol-4-one)-based analogues of the duocarmycins and CC-1065.

10. The method of claim 3 , wherein the cytotoxic agent is selected from doxorubicin and doxorubicin conjugates.

11. The method of claim 3 , wherein the cytotoxic agent is a dolastin selected from dolestatin-10, combretastatin, calicheamicin, maytansine, maytansine analogs, DM-I, auristatin E, auristatin EB (AEB), auristatin EFP (AEFP), monomethyl auristatin E (MMAE), 5-benzoyl valeric acid- AE ester (AEVB), tubulysins, disorazole, epothilones, Paclitaxel, docetaxel, SN-38, Topotecan, rhizoxin, echinomycin, colchicine, vinblastin, vindesine, estramustine, cemadotin, eleutherobin, methotrexate, methopterin, dichloro methotrexate, 5-fluorouracil, 6- mercaptopurine, cytosine arabinoside, melphalan, leurosine, leurosideine, actinomycin, daunorubicin and daunorubicin conjugates, mitomycin C, mitomycin A, carminomycin, aminopterin, tallysomycin, podophyllotoxin and podophyllotoxin derivatives such as etoposide or etoposide phosphate, vincristine, taxol, taxotere retinoic acid, butyric acid, N-acetyl spermidine, camptothecin, and analogs thereof.

12. The method of claim 1 , wherein the disease or disorder is an inflammatory disease or cancer.

13. The method of claim 12 , wherein the inflammatory disease is an autoimmune disease.

14. The method of claim 13 , wherein the autoimmune disease is rheumatoid arthritis, immune thromobcytopenic purpura, psoriasis, or lupus erythematosus.

15. The method of claim 12 , wherein the inflammatory disease is asthma.

16. The method of claim 12 , wherein the cancer is a solid tumor, lymphoma, or leukemia.

17. The method of claim 16 , wherein the solid tumor is breast cancer, melanoma, prostate cancer, benign prostatic hyperplasia, or colorectal cancer.

18. The method of claim 16 , wherein the lymphoma is non-Hodgkin's lymphoma.

19. The method of claim 16 , wherein the leukemia is chronic lymphocytic leukemia or acute myelogenous leukemia.

20. The method of claim 10 , wherein the doxorubicin and doxorubicin conjugates are morpholino-doxorubicin or cyanomorpholino-doxorubicin.